Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) have received a consensus rating of “Hold” from the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $4.63.

Several equities analysts recently issued reports on the company. Roth Capital assumed coverage on Galectin Therapeutics in a research note on Thursday. They set a “buy” rating and a $8.00 target price on the stock. Seaport Global Securities reissued a “buy” rating and set a $5.00 target price on shares of Galectin Therapeutics in a research note on Friday, October 6th. ValuEngine raised Galectin Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 28th. Finally, Zacks Investment Research lowered Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th.

Hedge funds have recently bought and sold shares of the business. KCG Holdings Inc. raised its position in Galectin Therapeutics by 1.9% in the 1st quarter. KCG Holdings Inc. now owns 86,195 shares of the company’s stock valued at $198,000 after purchasing an additional 1,592 shares in the last quarter. Advisor Group Inc. raised its position in Galectin Therapeutics by 10.4% in the 2nd quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock valued at $1,191,000 after purchasing an additional 45,700 shares in the last quarter. Virtu KCG Holdings LLC raised its position in Galectin Therapeutics by 24.4% in the 2nd quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after purchasing an additional 21,008 shares in the last quarter. Vanguard Group Inc. raised its position in Galectin Therapeutics by 18.2% in the 2nd quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after purchasing an additional 134,165 shares in the last quarter. Finally, Northern Trust Corp raised its position in Galectin Therapeutics by 4.4% in the 2nd quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares in the last quarter. 11.18% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/19/galectin-therapeutics-inc-galt-receives-consensus-recommendation-of-hold-from-analysts.html.

Galectin Therapeutics (NASDAQ:GALT) traded up 1.9880% during mid-day trading on Thursday, hitting $2.5599. The company had a trading volume of 235,396 shares. Galectin Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.68. The company’s market capitalization is $89.73 million. The company has a 50-day moving average price of $2.09 and a 200 day moving average price of $2.34.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Monday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same period last year, the business posted ($0.20) EPS. On average, analysts forecast that Galectin Therapeutics will post ($0.49) EPS for the current fiscal year.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.